Invention Grant
- Patent Title: Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
- Patent Title (中): 苯甲嘧啶，甲巯咪唑衍生物和互变异构环状硫堇用于治疗与同样受体过表达相关的自身免疫/炎性疾病
-
Application No.: US13370079Application Date: 2012-02-09
-
Publication No.: US09326972B2Publication Date: 2016-05-03
- Inventor: Leonard D. Kohn , Norikazu Harii , Uruguaysito Benavides-Peralta , Mariana Gonzalez-Murguiondo , Christopher J. Lewis , Douglas J. Goetz , Giorgio Napolitano , Cesidio Giuliani , Ramiro Malgor , Frank Schwartz , Kelly D. McCall
- Applicant: Leonard D. Kohn , Norikazu Harii , Uruguaysito Benavides-Peralta , Mariana Gonzalez-Murguiondo , Christopher J. Lewis , Douglas J. Goetz , Giorgio Napolitano , Cesidio Giuliani , Ramiro Malgor , Frank Schwartz , Kelly D. McCall
- Applicant Address: US OH Athens
- Assignee: Ohio University
- Current Assignee: Ohio University
- Current Assignee Address: US OH Athens
- Agency: Dinsmore & Shohl LLP
- Main IPC: A61K31/4164
- IPC: A61K31/4164 ; A61P31/04 ; A61P31/00 ; A61P29/00 ; A61K31/4166
Abstract:
Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.
Public/Granted literature
Information query
